Prometheus Laboratories Inc.

72 articles with Prometheus Laboratories Inc.

• Prometheus Laboratories Announces the Launch of PredictrPK™ IFX, A Revolutionary Test Enabling Precision-Guided Dosing for Inflammatory Bowel Disease

  2/17/2022

  Prometheus Laboratories Inc., a leader of precision healthcare, announced the launch of PredictrPK IFX, a test that aids healthcare providers with biologic dose optimization through individualized pharmacokinetic modeling.

• Prometheus Laboratories Announces Multiple Presentations on Precision-Guided Dosing and Monitoring at the Digestive Disease Week 2021 Annual Meeting

  5/11/2021

  Prometheus Laboratories, Inc. ("Prometheus"), a leader of precision healthcare, announced today multiple presentations and posters on precision-guided dosing and monitoring of Inflammatory Bowel Disease (IBD) at the virtual 2021 Digestive Disease Week

• 

  Recent Job Cuts in the Biopharma Industry

  10/7/2019

  BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.
• 

  57% of Americans OK with Genetically Engineering Animals for Organ Transplants

  9/19/2018

  A recent survey by the Pew Research Center found that 57 percent of Americans surveyed thought it was appropriate to use genetically engineered animals to grow organs for human transplants.
• 

  Researchers Take a Bite out of Bioengineering

  8/22/2018

  An article published earlier this summer in the Journal of Dental Research suggests that “bioengineered tooth buds” are a “superior alternative tooth replacement therapy.” In the article “Bioengineered Tooth Buds Exhibit Features of Natural Tooth Buds,” the authors report that artificial implants...

• Prometheus Laboratories Release: New Test Monitors Therapeutic Ustekinumab Levels In IBD Patients

  10/18/2017

  Prometheus Laboratories Inc. announces a new therapeutic drug monitoring test for use in adult inflammatory bowel disease (IBD) patients treated with Stelara (ustekinumab).

• Prometheus Laboratories Release: New Serum Test Is First to Measure and Monitor Mucosal Healing in Crohn's Disease

  10/17/2017

  Prometheus Laboratories introduces a comprehensive new serum test that measures and monitors mucosal healing status in Crohn's disease patients.

• Noninvasive PROMETHEUS FIBROSpect NASH Test Measures Severity of Liver Fibrosis

  10/17/2017

  Prometheus Laboratories introduces the FIBROSpect NASH test, a new tool to help healthcare providers stratify NASH patients by risk, based on the severity of their liver fibrosis.

• Prometheus Laboratories Inc. Release: Introducing PROMETHEUS IBcause: Convenient All-In-One Diagnostic Test For Persistent Diarrhea

  3/28/2017

• Prometheus Laboratories Inc. Release: PROMETHEUS Anser VDZ Test Validated For Use In Inflammatory Bowel Disease Patients

  10/12/2016

• Prometheus Laboratories Inc. Diagnostic Test Validated In Anticipation Of U.S. Healthcare Provider Demand For Celltrion's INFLECTRA (Biosimilar Infliximab)

  4/8/2016

• Prometheus Laboratories Inc. Release: PROCLAIM Patient Registry Data Demonstrates Safety And Efficacy Of Proleukin (Aldesleukin) When Sequenced With Immune Checkpoint Inhibitors In Metastatic Melanoma

  5/28/2015

• Prometheus Laboratories Inc. Release: PROCLAIM Patient Registry Data Demonstrate Survival Benefit Of First-Line Proleukin Therapy In Patients With Metastatic Renal Cell Carcinoma

  5/28/2015

• Prometheus Laboratories Inc. Release: New Data Show Proleukin (aldesleukin) Improves Patient Outcomes As First-Line Therapy For The Treatment Of Patients With Metastatic Melanoma Or Metastatic Renal Cell Carcinoma

  5/15/2015

• Prometheus Laboratories Inc. Release: PROCLAIM Patient Registry Data Show Extension Of Overall Survival Benefits Beyond Complete And Partial Responders In Metastatic Renal Cell Carcinoma Patients Treated With High-Dose Interleukin-2 (HD IL-2)

  5/30/2014

• Prometheus Laboratories Inc. Announces Inclusion of Proleukin&#0174 (Aldesleukin for Injection) / Interleukin-2 in SITC Guidelines for Treatment of Cutaneous Melanoma

  10/11/2013

• Prometheus Laboratories Inc. Appoints Chief Executive Officer

  9/19/2013

• Prometheus Laboratories Inc. Launches PROCLIVITY 02, a Phase IV Multi-Center Study Comparing the Sequence of Proleukin&#0174 (Aldesleukin for Injection) and Yervoy&#0174 (Ipilimumab) in Patients With Metastatic Melanoma

  5/30/2013

• Prometheus Laboratories Inc. Presents New Data On Growing IBD Diagnostic Portfolio at Digestive Disease Week 2013

  5/23/2013

• Prometheus Laboratories Inc. Launches PROCLIVITY(SM) 01 Clinical Trial of Proleukin&#0174 (Aldesleukin for Injection) Plus Vemurafenib Therapy in Patients with Metastatic Melanoma

  5/9/2013